All 1 tracked stories fall under one category: clinical-trial. Aligos Therapeutics is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. William Mccamey appears in 1 tracked Biotech story from August 9, 2026. The tracked stories average 2 original sources each.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about William Mccamey
All 1 tracked stories fall under one category: clinical-trial. Aligos Therapeutics is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. William Mccamey appears in 1 tracked Biotech story from August 9, 2026. The tracked stories average 2 original sources each.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 6 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering William Mccamey. Shared-story counts are live from our verified record — not editorial picks.
Aligos Therapeutics (ALGS) handily beat Q2 consensus earnings per share by $0.95, a significant outperformance for the clinical-stage biotech. This beat may reflect operational efficiencies, milestone payments, or clinical progress in its liver disease pipeline. Investors in the biotech space should watch for full financial disclosures to gauge the sustainability of this positive surprise.
